Dassault to enhance clinical tech with Medidata acquisition

 

Dassault Systèmes acquired U.S.-based Medidata, major player in information technologies for clinical trials, for $5.5 billion. This represents to date the largest buyout in the emerging area of in silico medicine and in silico trials and "a significant milestone to address the complexity of developing personalied medicine and patient-centric experiences".

It is expected that with the acquisition of Medidata, Dassault Systèmes will reinforce its position as a science-based company by providing the Life Sciences industry with an integrated business experience platform for an end-to-end approach to research and discovery, development, clinical testing, manufacturing and commercialization of new therapies and health technologies.